ZELTIA NEWS

Preliminary results from six trials with two PharmaMar compounds are presented at the EORTC conference

Madrid, 8 November 2012: PharmaMar, the biotechnology subsidiary of Grupo Zeltia (MC:ZEL), presented the results of six trials, five of them with lurbinectedin (PM01183) and one with Yondelis®, on 7 November at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, held in Dublin from 6 to

9 November. The presentation was given during the session entitled "Natural

Products and Marine Compounds".

The trials with lurbinectedin (PM01183) show that the compound induces a specific degradation of RNA polymerase II in tumour cells. This degradation, which is measured using a proteasome (a macromolecular complex whose function is protein degradation), requires competent TC-NER (Transcription Coupled- Nucleotide Excision Repair) DNA repair pathway and active transcription. Trials performed in animal models found that the distribution of lurbinectedin (PM01183) inside various types of tumour cells (pancreatic, ovarian and non-small cell lung cancer) ruptures the DNA double-strand, inducing apoptosis and, as a result, significantly reducing the size of the tumour. PharmaMar also described the ability of lurbinectedin (PM01183) and gemcitabine to produce a synergistic antitumour effect on xenotransplants of tumours in pancreatic, ovarian and non-small cell lung cancers by increasing apoptosis. This synergistic effect was confirmed in another trial (AVATAR), which shows that treatment with lurbinectedin (PM01183) and gemcitabine of patient-derived pancreatic adenocarcinomas xenotransplanted into mice was more effective than treatment with the individual compounds separately. PharmaMar also presented the compound's antimetastatic activity in a panel of experimental murine and human models.

As regards its other compound, the company presented a trial showing the synergistic effect on tumour lines of Yondelis® with AZD-2281 (olaparib), a PARP (Poly ADP Ribose Polymerase) inhibitor. This effect of Yondelis® and olaparib was observed in breast cancer cells with and without BRCA-1 gene expression. The


combination of Yondelis® with other PARP inhibitors (BSI-201 and ABT-888) had an additive effect on all of the cell lines in the trials.

About PharmaMar
PharmaMar is a biopharmaceutical subsidiary of Grupo Zeltia; it is a world leader in discovering, developing and selling marine-based drugs to treat cancer. Yondelis® is Spain's first antitumour drug. It is currently approved for soft tissue sarcoma (STS) in 39 countries outside the EEA, and for platinum- sensitive relapsed ovarian cancer (ROC) in 25 of those countries plus Brazil. Yondelis® is approved for STS and platinum-sensitive ROC in all 30 countries of the EEA. Yondelis® is also undergoing Phase II trials on breast and paediatric cancers. PharmaMar has four other compounds in clinical development: Aplidin®, Zalypsis®, PM01183 and PM060184. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D programme.
About Zeltia
Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine- based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genómica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.
Important note
PharmaMar, which is headquartered in Madrid (Spain), is a subsidiary of Zeltia, S.A. (Spanish stock exchange: ZEL), which has been listed on the Spanish Stock Exchange since 1963 and on Spain's Electronic Market since 1998. This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.
For more information +34 91 444 4500

This note is also available on the PharmaMar web site: www.pharmamar.comand at Zeltia's website:
www.zeltia.com

distributed by